SLC5A2 and metabolic syndrome: Results of multivariate logistic regression indicated that higher BMI, higher HbA1c level and having dyslipidemia increased the odds of using SGLT2 inhibitor, with an OR of 1.11 (95% CI 1.09–1.14), 1.13 (95% CI 1.09–1.17) and 3.43 (95% CI 2.57–4.58), respectively.